Document ID: FDA-2014-N-0554-0001
Agency: fda
Document Type: Notice
Title: Agency Information Collection Activities; Proposed Collection;
Comment Request; Comparative Price Information in Direct-to-Consumer and Professional Prescription Drug Advertisements
Posted Date: 2014-05-07T04:00Z

[Federal Register Volume 79, Number 88 (Wednesday, May 7, 2014)]
[Notices]
[Pages 26255-26257]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-10410]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0554]

Agency Information Collection Activities; Proposed Collection; 
Comment Request; Comparative Price Information in Direct-to-Consumer 
and Professional Prescription Drug Advertisements

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
opportunity for public comment on the proposed collection of certain 
information by the Agency. Under the Paperwork Reduction Act of 1995 
(the PRA), Federal Agencies are required to publish notice in the 
Federal Register concerning each proposed collection of information and 
to allow 60 days for public comment in response to the notice. This 
notice solicits comments on research entitled ``Comparative Price 
Information in Direct-to-Consumer and Professional Prescription Drug 
Advertisements.'' This study will investigate the impact of price 
comparison information in direct-to-consumer (DTC) and health care 
professional advertising for prescription drugs.

DATES: Submit either electronic or written comments on the collection 
of information by July 7, 2014.

ADDRESSES: Submit electronic comments on the collection of information 
to http://www.regulations.gov. Submit written comments on the 
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, 
Rockville, MD 20852. All comments should be identified with the docket 
number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, 
Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, 
MD 20850, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal 
Agencies must obtain approval from the Office of Management and Budget 
(OMB) for each collection of information they conduct or sponsor. 
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 
1320.3(c) and includes Agency requests or requirements that members of 
the public submit reports, keep records, or provide information to a 
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) 
requires Federal Agencies to provide a 60-day notice in the Federal 
Register concerning each proposed collection of information before 
submitting the collection to OMB for approval. To comply with this 
requirement, FDA is publishing notice of the proposed collection of 
information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.

Comparative Price Information in Direct-to-Consumer and Professional 
Prescription Drug Advertisements--(OMB Control Number 0910--NEW)

    Section 1701(a)(4) of the Public Health Service Act (42 U.S.C. 
300u(a)(4)) authorizes FDA to conduct research relating to health 
information. Section 1003(d)(2)(C) of the Federal Food, Drug, and 
Cosmetic Act (the FD&C Act) (21 U.S.C. 393(d)(2)(C)) authorizes FDA to 
conduct research relating to drugs and other FDA regulated products in 
carrying out the provisions of the FD&C Act.
    By their very nature, medical and health decisions are comparative 
(e.g., treat versus not treat). For consumers, these decisions may 
include the use of prescription drug products versus over the counter 
products versus herbal

[[Page 26256]]

supplements, as well as one prescription brand versus another 
prescription brand. Similarly, advertising is often comparative. In 
prescription drug advertising, sponsors are permitted to include 
truthful, non-misleading information about the price of their products 
in promotion. This may extend to price comparison information, wherein 
sponsors may include information about the price of a competing product 
in order to make advantageous claims. Currently, when price comparisons 
are made, the ad should also include context that the two drugs may not 
be comparable in terms of efficacy and safety and that the acquisition 
costs presented do not necessarily reflect the actual prices paid by 
consumers, pharmacies, or third party payers. Despite the inclusion of 
this additional information, there is concern that adding contextual 
information about efficacy or safety is not sufficient to correct the 
impression that the products are interchangeable and that price is the 
main factor to consider. The Office of Prescription Drug Promotion 
(OPDP) plans to investigate, through empirical research, the impact of 
price comparison information and additional contextual information on 
prescription drug product perceptions. This will be investigated in DTC 
and healthcare-directed professional advertising for prescription 
drugs.
    We will investigate perceptions about overall drug safety and 
efficacy and perceptions of the comparator product. To examine 
differences between experimental conditions, we will conduct 
inferential statistical tests such as analysis of variance. With the 
sample size described in this document, we will have sufficient power 
to detect small-to-medium sized effects in the main study.
    Participants will be consumers who self-identify as having been 
diagnosed with diabetes and physicians who are General Practitioners 
(e.g., Family Practice, General Practice, Internal Medicine) and 
Specialists (e.g., Endocrinology, Pain Management). All participants 
will be 18 years of age or older. We will exclude individuals from the 
consumer sample who work in healthcare or marketing settings because 
their knowledge and experiences may not reflect those of the average 
consumer. Recruitment and administration of the study will take place 
over the Internet. Participation is estimated to take approximately 30 
minutes.
    Physician and consumer participants will be randomly assigned to 
view one of three possible versions of an ad (DTC or professional), as 
depicted in table 1. One version will present information about the 
price of the product relative to a competitor for the same indication 
(price comparison information). Another version will present this 
information with additional contextual information that the two drugs 
may not be comparable in terms of efficacy and safety and that the 
acquisition costs do not necessarily reflect actual prices paid. A 
third version will have a claim about the price of the product but will 
not present information about the price relative to a competitor, and 
will act as a control.
    After viewing the ad, participants will respond to questions about 
information in the ad. Preliminary measures are designed to assess 
perception and understanding of product safety and efficacy; perception 
and understanding of the additional contextual information; perceptions 
of comparative safety and efficacy; and intention to seek more 
information about the product. The questionnaire is available upon 
request.

                                              Table 1--Study Design
----------------------------------------------------------------------------------------------------------------
                                                                         Type of price comparison
                                                        --------------------------------------------------------
                         Sample                                             Price information    No comparison
                                                         Price information     + additional       information
                                                                only             context           (control)
----------------------------------------------------------------------------------------------------------------
Consumers (DTC ad)
Physicians (Professional ad)                             .................  .................  .................
----------------------------------------------------------------------------------------------------------------

    FDA estimates the burden of this collection of information as 
follows:

                                                     Table 2--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                 Number of
                  Activity                       Number of     responses per   Total annual           Average burden per response           Total hours
                                                respondents     respondent       responses
--------------------------------------------------------------------------------------------------------------------------------------------------------
Sample outgo (pretests and main survey).....          41,110  ..............  ..............  ..........................................  ..............
Screener completes..........................           7,400               1           7,400  .03 (2 minutes)...........................             222
Eligible....................................           4,933  ..............  ..............  ..........................................  ..............
Completes, Pretests Phase 1.................             400               1             400  0.5 (30 minutes)..........................             200
Completes, Pretest Phase 2..................           1,000               1           1,000  0.5 (30 minutes)..........................             500
Completes, Main Study.......................           2,940               1           2,940  0.5 (30 minutes)..........................           1,470
                                             -----------------------------------------------------------------------------------------------------------
    Total...................................  ..............  ..............  ..............  ..........................................           2,392
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.

[[Page 26257]]

    Dated: May 1, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-10410 Filed 5-6-14; 8:45 am]
BILLING CODE 4160-01-P